Citigroup’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-30,000
Closed -$123K – 6333
2025
Q4
$123K Buy
+30,000
New +$149K ﹤0.01% 4234
2025
Q1
– Sell
-22,100
Closed -$149K – 5911
2024
Q4
$149K Buy
+22,100
New +$149K ﹤0.01% 4616
2024
Q2
– Sell
-62,700
Closed -$625K – 5753
2024
Q1
$625K Buy
+62,700
New +$698K ﹤0.01% 3418

Other funds holding RXRX

Citigroup's RXRX Position: Q3 2026 in Review

Citigroup reduced its Recursion Pharmaceuticals (RXRX) stake by 58% in Q3 2026, selling an estimated $1.7M and leaving 363,644 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3031.

Citigroup first reported a position in RXRX in Q2 2021 and has held it in 22 quarters since. The position peaked at $7.99M in Q1 2024. 353 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • Citigroup held 363,644 shares of Recursion Pharmaceuticals worth $1.5M as of Q3 2026.
  • Citigroup sold 500,759 Recursion Pharmaceuticals shares in Q3 2026, an estimated $1.7M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3031 holding.
  • Citigroup first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 22 quarters since.
  • Citigroup's Recursion Pharmaceuticals position peaked at $7.99M in Q1 2024.
  • 353 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.